01 What is Follistatin?
In plain English.
Follistatin is a protein your body makes naturally. Its main job in this context is to grab onto another protein called myostatin and switch it off. Myostatin acts as a brake on muscle growth — it tells muscles to stop getting bigger. When myostatin is blocked, muscles can grow much larger than normal. Animals genetically engineered to lack myostatin (the famous "double-muscled" cattle, mice and dogs) are dramatically more muscular. That single fact is the entire reason follistatin became a fixation in bodybuilding circles. The catch is that the version sold to bodybuilders — an injectable labelled "follistatin-344" — is not the gene therapy that produced those animal results, and there is no controlled human trial showing it works.
There are two completely different things both called "follistatin", and conflating them is where the hype comes from. The first is gene therapy: a viral vector that makes muscle tissue produce follistatin continuously, studied in muscular-dystrophy trials. The second is a vial of injectable peptide sold by research-chemical vendors as "follistatin-344". The striking muscle results belong almost entirely to the first; the product people actually buy is the second, and it has essentially no controlled human efficacy data behind it. Popular is not the same as proven.
02 How it works
The simple version, then the science.
Muscle has a built-in growth limiter called myostatin (also written GDF-8). Myostatin's job is to stop muscle from growing past a certain point. Follistatin works by physically binding to myostatin and neutralising it — taking the foot off the brake. With the brake released, the signals that drive muscle growth can run unopposed, which in animals leads to larger muscles. In theory, injecting follistatin should do the same in humans. In practice, a short-lived protein injected under the skin is a very different proposition from genetically reprogramming muscle to pump out follistatin continuously, which is how the impressive animal results were actually achieved.
Go deeper · the proposed mechanism
Follistatin is a secreted glycoprotein that binds members of the TGF-β superfamily with high affinity — principally myostatin (GDF-8) but also activin A and other ligands. Myostatin normally signals through the activin type IIB receptor (ActRIIB) and its co-receptors, recruiting ALK4/ALK5 and driving SMAD2/3 phosphorylation, which suppresses muscle protein accretion. By sequestering myostatin (and activin) before they reach ActRIIB, follistatin removes that inhibitory SMAD signalling, permitting hypertrophy. The crucial gap between animal headlines and the marketed peptide is delivery and exposure: the dramatic "double-muscled" and dystrophy results come from AAV gene therapy that drives sustained [intramuscular](/glossary "Intramuscular: Injected into muscle tissue; typically a deeper, larger volume than a subcutaneous injection.") follistatin expression for months. An injected recombinant or research-grade peptide is cleared within hours, may not fold or glycosylate correctly, and has never been shown in a controlled human trial to produce meaningful, lasting hypertrophy. Because follistatin also binds activin — which has roles well beyond muscle — broad systemic inhibition is not a clean, muscle-only intervention.
03 What it's used for
Each use graded by how strong the evidence actually is.
- PreclinicalMuscle growth via myostatin inhibition (animal / gene therapy)🔬 Myostatin loss-of-function produces dramatic muscle hypertrophy in mice, cattle and dogs (McPherron et al., Nature 1997; Mosher et al., PLoS Genetics 2007). Follistatin over-expression delivered by AAV gene therapy increases muscle mass and strength in animal models. This is genuine, strong preclinical science — but it describes gene therapy and animals, not an injected peptide in humans.
- PreclinicalMuscular dystrophy / muscle-wasting (gene-therapy trials)🔬 Follistatin gene therapy (AAV-delivered) has been tested in early-phase trials for Becker and inclusion-body myositis muscular dystrophies (Mendell et al., Molecular Therapy 2015), with safety and some functional signals reported in very small samples. These are experimental gene-therapy studies, not validation of an over-the-counter injectable.
- AnecdotalBodybuilding "muscle gain" / recomposition with injectable follistatin-344💬 The dominant real-world use. Forums and vendors claim rapid muscle gains from injecting "follistatin-344". There is no controlled human trial supporting this, contents and dosing are unverified, and reports are uncontrolled anecdote. Treat efficacy claims as unproven.
- AnecdotalFaster recovery / anti-myostatin "anti-ageing"💬 Sometimes marketed for recovery or age-related muscle loss. No human efficacy evidence supports an injected peptide for these uses; the rationale is extrapolated from animal and gene-therapy work.
04 What the evidence says
The honest summary has two halves that the marketing deliberately blurs. The myostatin biology is solid and striking: mice engineered to lack myostatin (McPherron et al., Nature 1997) are roughly twice as muscular, and natural myostatin mutations explain the "double-muscled" Belgian Blue cattle, the bully whippet (Mosher et al., PLoS Genetics 2007), and a documented case of a hypermuscular child (Schuelke et al., NEJM 2004). Delivering follistatin by AAV gene therapy increases muscle mass in animals, and early-phase human gene-therapy trials in muscular dystrophy (Mendell et al., Molecular Therapy 2015) reported acceptable safety and some functional signal in tiny samples. That is where the impressive evidence stops. There is no randomised controlled trial showing that an injected "follistatin-344" peptide — the thing actually sold to bodybuilders — produces meaningful, lasting muscle growth in healthy humans. A short-lived protein injected subcutaneously is a fundamentally different intervention from sustained intramuscular gene expression, and research-grade material may not even be correctly folded or active. On top of that, broad inhibition of myostatin and activin signalling is not a clean muscle-only effect: these pathways operate in reproduction, the cardiovascular system and tumour biology, which is exactly why pharmaceutical myostatin-inhibitor programmes have repeatedly stalled. So: strong, real preclinical and gene-therapy science; essentially zero controlled human efficacy evidence for the marketed peptide; and unresolved safety concerns. Grade D reflects that gap, not the strength of the underlying biology.
05 Dosing & administration
Reported in the literature, information not advice.
For context only — this is not advice, and there is no validated protocol to follow. There is no approved follistatin medicine, no established human dose, and no clinical pharmacokinetic profile for the injectable "follistatin-344" products sold online. Forum "protocols" are uncontrolled anecdote built around unverified material of unknown purity, concentration and sterility, and cannot be made safe by copying a number from a thread. The gene-therapy studies that produced real results used a viral vector under hospital conditions, not a self-administered subcutaneous peptide, so they offer no usable dosing guidance for an injectable product. We do not provide muscle-building protocols or administration instructions.
06 Side effects & safety
Two layers of risk. The first is biological. Follistatin does not only block myostatin — it also binds activin and related signalling molecules that operate well beyond muscle, including in reproduction (the pituitary–gonadal axis), the cardiovascular system, and cell-growth control relevant to tumour biology. Broadly suppressing these pathways is not a clean, muscle-only intervention, and the theoretical concern that sustained myostatin/activin inhibition could affect reproductive function or influence tumour behaviour is one reason pharmaceutical myostatin-inhibitor programmes have repeatedly run into trouble. The long-term consequences of injecting follistatin in healthy people are simply not characterised. The second layer is supply. "Follistatin-344" sold by research-chemical vendors is unregulated: purity, dose accuracy, sterility, endotoxin content and whether the protein is even active are all unverifiable, adding infection and contamination risk on top of the unknown pharmacology. People who are pregnant or breastfeeding, anyone with a personal or family history of cancer, and anyone with cardiovascular disease should be especially wary given the pathways involved. There is no clinician overseeing non-trial use, and no way to make an unproven injectable from an unregulated source safe.
07 Where to buy
Sold "research use only", so verification matters more than price.
08 Legal & regulatory status
- UKNot licensed by the MHRA. No approved follistatin medicine exists. Material sold as "follistatin-344" is an unregulated research chemical with no legitimate UK supply chain.
- USNot FDA-approved. Sold only as a research-use-only chemical, not for human use; there is no compounding pathway because no approved product exists.
- EUNot authorised by the EMA. Unapproved; research-chemical status only.
- Sport
09 Clinical studies & research
Primary sources. Read the science yourself.